The spectrum of urological malignancy in Lynch syndrome

Familial Cancer

Volumn 12, Issue 1, 2013, Pages 57-63

  Barrow, P J ^a,b   Ingham, S ^b,d   O'Hara, C ^c   Green, K ^b   McIntyre, I ^a   Lalloo, F ^b   Hill, J ^a   Evans, D G ^b  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

^c North West Cancer Intelligence Service ^*  (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Bladder cancer; Hereditary nonpolyposis colorectal cancer; Lynch syndrome; Prostate cancer; Relative risk; Urological malignancy

Indexed keywords

MISMATCH REPAIR PROTEIN; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6;

ADULT; ARTICLE; BLADDER CANCER; CANCER INCIDENCE; CANCER RISK; CANCER SUSCEPTIBILITY; DNA SEQUENCE; FOLLOW UP; GENE MUTATION; GENETIC ASSOCIATION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HETEROZYGOTE; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY PELVIS CANCER; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; URETER CANCER; URINARY TRACT CANCER;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; COLORECTAL NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; UROLOGIC NEOPLASMS; YOUNG ADULT;

EID: 84873414349     PISSN: 13899600     EISSN: 15737292     Source Type: Journal    
DOI: 10.1007/s10689-012-9573-z     Document Type: Article

References (26)

1. Bonis PA, Trikalinos TA, Chung M, Chew P, Ip S, DeVine D et al. (2007) Hereditary Nonpolyposis colorectal cancer: diagnostic strategies and their implications. Evidence report/technology assessment no. 150 (Prepared by Tufts-New England Medical Center Evidence-based Practice Center under Contract No. 290-02-0022). AHRQ Publication No. 07-E008. Agency for Healthcare Research and Quality, Rockville
2. Vasen HF, Moslein G, Alonso A, Bernstein I, Bertario L, Blanco I et al (2007) Guidelines for the clinical management of lynch syndrome (hereditary non-polyposis cancer). J Med Genet 44(6):353-362
3. Cairns SR, Schofield JH, Steele RJ, Dunlop MG, Thomas HJ, Evans GD et al (2010) Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 59:666-690
4. Roupret M, Yates DR, Comperat E, Cussenot O (2008) Upper urinary tract urothelial cell carcinomas and other urological malignancies involved in the hereditary nonpolyposis colorectal cancer (lynch syndrome) tumor spectrum. Eur Urol 54:1226-1236
5. Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Ruschoff J et al (2004) Revised bethesda guidelines for hereditary nonpolyposis colorectal cancer (lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96:261-268
6. Barrow E, Robinson L, Alduaij W, Shenton A, Clancy T, Lalloo F et al (2009) Cumulative lifetime incidence of extracolonic cancers in lynch syndrome: a report of 121 families with proven mutations. Clin Genet 75:141-149
7. Watson P, Riley B (2005) The tumor spectrum in lynch syndrome. Fam Cancer 4:245-248
8. Watson P, Vasen HFA, Mecklin JP, Bernstein I, Aarnio M, Jarvinen HJ et al (2008) The risk of extra-colonic, extra-endometrial cancer in the lynch syndrome. Int J Cancer 123(2):444-449
9. Vasen HFA, Stormorken A, Menko FH, Nagengast FM, Kleibeuker JH, Griffioen G et al (2001) MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. J Clin Oncol 19(20):4074-4080
10. Wagner DG, Gatalica Z, Lynch HT, Kohl S, Johansson SL, Lele SM (2010) Neuroendocrine-type prostatic adenocarcinoma with microsatellite instability in a patient with lynch syndrome. Int J Surg Pathol 18(6):550-553
11. Bauer CM, Ray AM, Halstead-Nussloch BA, Dekker RG, Raymond VM, Gruber SB et al (2011) Hereditary prostate cancer as a feature of lynch syndrome. Fam Cancer 10(1):37-42
12. Grindedal EM, Moller P, Eeles R, Stormorken AT, Bowitz-Lothe IM, Landro SM et al (2009) Germ-line mutations in mismatch repair genes associated with prostate cancer. Cancer Epidemiol Biomarkers Prev 18(9):2460-2467
13. Van der Post RS, Kiemeney LA, Ligtenberg MJL, Witjes JA, Hulsbergen-van de Kaa CA, Bodmer D et al (2010) Risk of urothelial bladder cancer in lynch syndrome is increased, in particular among msh2 mutation carriers. J Med Genet 47:464-470
14. Koornstra JJ, Mourits MJE, Sijmons RH, Leliveld AM, Hollema H, Kleibeuker JH (2009) Management of extracolonic tumours in patients with lynch syndrome. Lancet Oncol 10:400-408
15. Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S et al (2012) Radical prostatectomy versus observation for localised prostate cancer. NEJM 367(3):203-213
16. Hoffman RM (2011) Screening for prostate cancer. N Engl J Med 365(21):2013-2019
17. Breslow NE, Day NE (1987) Statistical methods in cancer research Vol II. The design and analysis of cohort studies (IARC Scientific Publication No 82). International Agency for Research on Cancer, Lyon
18. Cancer Research UK (2009) Available from http://info.cancerresearchuk. org/cancerstats/mortality/cancerdeaths/#Top
19. Soravia C, Van der Klift H, Brundler M, Blouin JL, Wijnen J, Hutter P et al (2003) Prostate cancer is part of the hereditary non-polyposis colorectal cancer (HNPCC) tumour spectrum. Am J Med Genet 121((A)):159-162
20. Bratt O (2000) Hereditary prostate cancer. Br J Urol 85:588-598
21. Impact-study.com. Available from http://www.impact-study.com
22. Fredriksson H, Ikonen T, Autio V, Matikainen MP, Helin HJ, Tammela TLJ et al (2006) Identification of germline MLH1 alterations in familial prostate cancer. Eur J Cancer 42:2802-2806
23. Chen Y, Wang J, Fraig MM, Metcalf J, Turner WR, Bissada NK et al (2001) Defects of DNA mismatch repair in human prostate cancer. Cancer Res 61:4112-4121
24. Goeke T, Schulmann K, Engel C, Holinski-Feder E, Pagenstecher C, Schackert HK et al (2006) Genotype-phenotype comparison of german mlh1 and msh2 mutation carriers clinically affected with lynch syndrome: a report by the german hnpcc consortium. J Clin Oncol 24(26):4285-4292
25. Bermejo JL, Eng C, Hemminki K (2005) Cancer characteristics in swedish families fulfilling criteria for hereditary nonpolyposis colorectal cancer. Gastroenterology 129:1889-1899
26. Win AK, Young JP, Lindor NM, Tucker KM, Ahnen DJ, Young GP et al (2012) Colorectal and other cancer risks for carriers and non-carriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J Clin Oncol 30(9):958-964